Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013450 · ClinicalTrials.gov registry record · Phase 1
Dupilumab_Metastatic NSCLC
A Phase 1 study of Metastatic Non Small Cell Lung Cancer, sponsored by Thomas Marron.
- Active
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT05013450: Active Phase 1 study of Metastatic Non Small Cell Lung Cancer, sponsored by Thomas Marron.
NCT05013450 is a Phase 1 study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Thomas Marron. The registered enrollment target is 33 participants, below the 381-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013450, a Phase 1 study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Thomas Marron.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi cohort, sequential enrollment clinical trial to determine the safety and tolerability of Dupilumab and Anakinra with PD-(L)1 blockade for patients with relapsed/refractory metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra and IL-1R blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents.
Primary Outcome
Phase 1: Dose Limiting Toxicity (DLTs) as defined based on the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0.
Conditions Studied
Interventions
- DRUG Dupilumab
- DRUG Anakinra
- DRUG PD-1/PD-L1 blockade
Study Locations (1)
New York
- Tisch Cancer Institute, Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2025-12-09 |
| Phase | Phase 1 |
What the registry record for NCT05013450 still lists
NCT05013450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 381-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dupilumab is the first listed.
NCT05013450 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05013450 about?
NCT05013450 is a clinical study titled "Dupilumab_Metastatic NSCLC". This is a multi cohort, sequential enrollment clinical trial to determine the safety and tolerability of Dupilumab and Anakinra with PD-(L)1 blockade for patients with relapsed/refractory metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra and IL-1R blockade to PD-(L)1 blocking a...
What is the current status of trial NCT05013450?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2021-09-10. Estimated completion is 2025-12-09.
What conditions does trial NCT05013450 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT05013450?
The interventions under investigation include: Dupilumab (DRUG), Anakinra (DRUG), PD-1/PD-L1 blockade (DRUG).
Who is sponsoring clinical trial NCT05013450?
This trial is sponsored by Thomas Marron, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013450 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05013450's enrollment target sits among peer trials
33 27th of 31 higher than 5 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RECRUITING · Phase 1
-
MOv19-BBz CAR T Cells in FRa+ Cancers
RECRUITING · Phase 1
-
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
-
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI